skin cancer Castle Biosciences Q1 Revenues Grow 18 Percent The Friendswood, Texas-based molecular diagnostics company reported revenues of $26.9 million in Q1 2022, up from $22.8 million a year ago. DermTech Posts 48 Percent Jump in Q1 Revenues Despite the revenue increase, the La Jolla, California-based skin cancer diagnostics firm missed Wall Street's revenue and earnings expectations. Castle Biosciences, VHA Expand Supply Contract to Cover Full Skin Cancer Test Portfolio The new contract with the Veterans Health Administration makes all five of the company's skin cancer assays available for veterans, active-duty military, and family members. DermTech Q4 Revenues Jump 52 Percent, Miss Wall Street Estimate The company's revenue gains were driven by higher sales of its noninvasive skin cancer tests. Castle Biosciences Q4 Revenues Grow 45 Percent The molecular diagnostics company said it delivered 33 percent more DecisionDx-Melanoma test results in Q4 2021 than in the previous year's fourth quarter. Nov 16, 2021 Cancer Genomic Analysis Reveals Distinct Features in Tumors From Patients Under 50 Years Old Nov 9, 2021 Dermtech Q3 Revenues Rise 122 Percent Nov 8, 2021 Castle Biosciences Q3 Revenues Rise 54 Percent Oct 27, 2021 Castle Biosciences Buy of Cernostics Aligns With Goal to Diversify Portfolio Premium Sep 16, 2021 Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test Aug 24, 2021 Castle Biosciences Awarded VA Supply Contract for Melanoma Test Aug 9, 2021 Castle Biosciences Q2 Revenues Rise 79 Percent Jun 9, 2021 Castle Biosciences Receives NYS DOH Approval for Skin Cancer Diagnostic May 11, 2021 Castle Biosciences to Expand Range of Dermatology Diagnostics Beyond Cancer Premium May 10, 2021 Castle Biosciences Q1 Revenues Up 31 Percent Mar 11, 2021 Eye Color GWAS Leads to 50 New Loci, Underscoring Trait's Complexity Mar 8, 2021 Castle Biosciences Q4 Revenues Down 2 Percent Mar 5, 2021 DermTech Q4 Revenues Up 31 Percent Feb 16, 2021 Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases Feb 12, 2021 DermTech Enters Agreement With Blue Cross Blue Shield of Texas for Skin Cancer Assay Jan 7, 2021 DermTech Prices $125M Public Offering of Common Stock Jun 22, 2020 Genomic Study Reveals Recurrent Cutaneous Melanoma Alterations, Male-Specific Mutations Jun 5, 2020 Secondary Tumor Risk in Pediatric Cancer Survivors Linked to Germline Variants, Treatment Type Apr 27, 2020 Cutaneous Melanoma Clues Found From Risky SNPs, Related Traits Analyses Mar 9, 2020 DermTech Trying to Drum up Payor Coverage for Melanoma Test With Study Results Premium Load More Breaking News Mitochondrial Protein Resource Reveals New Disease Players StageZero Life Sciences, DiagnoseAtHome Partner on Multicancer Blood Test OraSure Technologies Selected by HHS to Provide COVID-19 School Testing Hologic Obtains CE Mark for Molecular Epstein-Barr, BK Virus Assays Multiomics Startup Pleno Closes $15M Funding Round SeekIn Gets CE Mark for Cancer Treatment Response Monitoring Kit The Scan UK Moves to Allow Sale of Gene-Edited Food The UK is moving ahead to allow the sale of gene-edited food in England, Scotland, and Wales, according to New Scientist. Questions for the Field Stat News writes that the alleged Buffalo shooter's citation of genetics research raises questions about what the field can do. Cell Studies on Tumor Evolution in Mouse Model of Lung Cancer, Stereo-seq, Bacteriophage Responses In Cell this week: tumor evolution tracked in mouse model of lung cancer, organogenesis mapped using Stereo-seq, and more. Taking Stock of the Stockpile The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.